Advanced search
Publication Cover
Cancer Management and Research Volume 16, 2024 - Issue
Submit an article Journal homepage
22
Views
0
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Human Equilibrative Nucleoside Transporter 1: Novel Biomarker and Prognostic Indicator for Patients with Gemcitabine-Treated Pancreatic Cancer

Jianchun Xiao1 Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, People’s Republic of ChinaView further author information
,
Fangyu Zhao1 Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, People’s Republic of ChinaView further author information
,
Wenhao Luo1 Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0001-9914-5338View further author information
ORCID Icon,
Gang Yang1 Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, People’s Republic of ChinaView further author information
,
Yicheng Wang1 Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, People’s Republic of ChinaView further author information
,
Jiangdong Qiu1 Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, People’s Republic of ChinaView further author information
,
Yueze Liu1 Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, People’s Republic of ChinaView further author information
,
Lei You1 Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, People’s Republic of ChinaView further author information
,
Lianfang Zheng2 Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, People’s Republic of ChinaView further author information
&
Taiping Zhang1 Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, People’s Republic of China;3 Clinical Immunology Center, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, People’s Republic of ChinaCorrespondence[email protected]
View further author information
 show all
Pages 651-661 | Received 28 Mar 2024, Accepted 23 May 2024, Published online: 20 Jun 2024

References

  • Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12–49. doi:10.3322/caac.21820
  • Ashrafizadeh M, Luo K, Zhang W, Reza Aref A, Zhang X. Acquired and intrinsic gemcitabine resistance in pancreatic cancer therapy: environmental factors, molecular profile and drug/nanotherapeutic approaches. Environ Res. 2024;240:117443. doi:10.1016/j.envres.2023.117443
  • Ashrafizadeh M, Zhang W, Zou R, Sethi G, Klionsky DJ, Zhang X. A bioinformatics analysis, pre-clinical and clinical conception of autophagy in pancreatic cancer: complexity and simplicity in crosstalk. Pharmacol Res. 2023;194:106822. doi:10.1016/j.phrs.2023.106822
  • Zhang W, Fan Y, Zhang J, et al. Cell membrane-camouflaged bufalin targets NOD2 and overcomes multidrug resistance in pancreatic cancer. Drug Resist Updat. 2023;71:101005. doi:10.1016/j.drup.2023.101005
  • Yuan J, Zhu Z, Zhang P. SKP2 promotes the metastasis of pancreatic ductal adenocarcinoma by suppressing TRIM21-mediated PSPC1 degradation. Cancer Lett. 2024;587:216733. doi:10.1016/j.canlet.2024.216733
  • Oettle H, Neuhaus P, Hochhaus A, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA. 2013;310(14):1473–1481. doi:10.1001/jama.2013.279201
  • Binenbaum Y, Na’ara S, Gil Z. Gemcitabine resistance in pancreatic ductal adenocarcinoma. Drug Resist Updat. 2015;23:55–68. doi:10.1016/j.drup.2015.10.002
  • Huang W, Zeng X, Shi Y, Liu M. Functional characterization of human equilibrative nucleoside transporter 1. Protein Cell. 2017;8(4):284–295. doi:10.1007/s13238-016-0350-x
  • Nordh S, Ansari D, Andersson R. hENT1 expression is predictive of gemcitabine outcome in pancreatic cancer: a systematic review. World J Gastroenterol. 2014;20(26):8482–8490. doi:10.3748/wjg.v20.i26.8482
  • Bird NTE, Elmasry M, Jones R, et al. Immunohistochemical hENT1 expression as a prognostic biomarker in patients with resected pancreatic ductal adenocarcinoma undergoing adjuvant gemcitabine-based chemotherapy. Br J Surg. 2017;104(4):328–336. doi:10.1002/bjs.10482
  • Sierzega M, Pach R, Kulig P, et al. Prognostic Implications of Expression Profiling for Gemcitabine-Related Genes (hENT1, dCK, RRM1, RRM2) in Patients With Resectable Pancreatic Adenocarcinoma Receiving Adjuvant Chemotherapy. Pancreas. 2017;46(5):684–689. doi:10.1097/MPA.0000000000000807
  • Belkouz A, Labeur TA, Dierks J, et al. Prognostic immunohistochemical biomarkers of chemotherapy efficacy in biliary tract cancer: a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2019;141:82–94. doi:10.1016/j.critrevonc.2019.06.001
  • Brandi G, Deserti M, Vasuri F, et al. Membrane Localization of Human Equilibrative Nucleoside Transporter 1 in Tumor Cells May Predict Response to Adjuvant Gemcitabine in Resected Cholangiocarcinoma Patients. Oncologist. 2016;21(5):600–607. doi:10.1634/theoncologist.2015-0356
  • Vincenzi B, Stacchiotti S, Collini P, et al. Human equilibrative nucleoside transporter 1 gene expression is associated with gemcitabine efficacy in advanced leiomyosarcoma and angiosarcoma. Br J Cancer. 2017;117(3):340–346. doi:10.1038/bjc.2017.187
  • Poplin E, Wasan H, Rolfe L, et al. Randomized, multicenter, Phase II study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma: including a prospective evaluation of the role of hENT1 in gemcitabine or CO-101 sensitivity. J Clin Oncol. 2013;31(35):4453–4461. doi:10.1200/JCO.2013.51.0826
  • Sinn M, Riess H, Sinn BV, et al. Human equilibrative nucleoside transporter 1 expression analysed by the clone SP 120 rabbit antibody is not predictive in patients with pancreatic cancer treated with adjuvant gemcitabine - Results from the CONKO-001 trial. Eur J Cancer. 2015;51:1546–1554. doi:10.1016/j.ejca.2015.05.005

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.